Mutations linked to therapy targets in AML, such as FLT3 and IDH1/2, are more frequently identified in NPM1mut AML, whereas KMT2A, TP53, and myelodysplastic-related mutations are more frequently identified in NPM1wt AML. This evidence concerns the gene KMT2A and acute myeloid leukemia.